Company Spotlight

News about our PABC Member Companies

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Aprea Therapeutics, Inc. announced new preclinical data and a clinical update on APR-1051, the Company’s next-generation oral WEE1 inhibitor, in human papillomavirus–positive (HPV+) head and neck squamous cell carcinoma (HNSCC).

6/25/2025

Sterotherapeutics Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating ST-002 for Cushing's Syndrome

Sterotherapeutics LLC, a clinical-stage biopharmaceutical company focused on rare endocrine diseases, announced that the first patient has been successfully dosed in its ongoing Phase 2 clinical trial evaluating ST-002 for the treatment of Cushing's Syndrome.

6/24/2025

WeTrhivv: Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum

REVIVV® is a topical serum supplement, containing vitamins, minerals, proteins, and nutraceutical-grade botanical bioactives designed to restore hair health. The formulation of botanicals includes potent anti-inflammatory, anti-stress adaptogenic, antioxidant, and DHT-inhibiting properties tailored to the specific needs of men and women.

4/1/2025

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center.

3/12/2025

Rajant Health and Incite Health Join Forces to Advance Precision Medicine and Remote Healthcare Solutions

Rajant Health Incorporated (RHI) and Incite Health, both leaders in advanced healthcare technologies, are collaborating to leverage their expertise toward the advancement of precision medicine and healthcare insight solutions. The partnership will continue to bring new technology-based solutions to the care of our civilian and military customers, provide access and equity to underserved populations, while setting new standards across the healthcare industry.

2/25/2025

The Alliance for Health Equity Receives $110,000 Donation for Catalytic Impact Fund

Of the $110,000 donation, $100,000 will be used to purchase shares in Merlin Biotechnology, a pharmaceutical firm dedicated to developing cancer treatments, including therapies for Ewing’s Sarcoma, a rare pediatric cancer. Ewing’s Sarcoma has limited treatment options due to its rarity, making it less attractive to large pharmaceutical companies focused on financial returns.

12/23/2024

CELLTREAT Acquires Brewster Plastics

CELLTREAT® Scientific Products (“CELLTREAT”) is excited to welcome Brewster Plastics into the CELLTREAT portfolio. Brewster Plastics is a leading US-based injection molding manufacturer of precision plastics. This addition strengthens CELLTREAT’s commitment to expanding its domestic production capabilities, expediting delivery times, and improving product quality for its valued customers.

11/13/2024

Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Gylden Pharma, a clinical-stage biotechnology company addressing major global infectious diseases through the development of synthetic T cell-priming vaccine candidates, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (Bethesda, MD, USA), has selected Emergex for inclusion in its Project NextGen.

10/02/2024

FCTDI is pleased to report that troriluzole has achieved positive topline results in a pivotal study for the treatment of spinocerebellar ataxia

Troriluzole was designed and prepared at FCTDI funded originally by multiple SBIR grants from the National Institutes of Health. Biohaven acquired the rights to troriluzole and related prodrugs of riluzole in Aug., 2015.

9/24/2024

Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity

PABC members, Evrys Bio and Conifer Point Pharmaceuticals, recently were featured in a special issue on sirtuins in Pharmaceuticals.

9/15/2024

Merlin Biotech, a Pennsylvania startup and PABC-member company focused on hard-to-treat cancers, announces major milestones

The U.S. Food and Drug Administration has conditionally designated Merlin Biotech Inc.’s marketing application for MER-101 as a “rare pediatric disease product application” pending the final determination whether the application meets all of the eligibility criteria set forth in section529(a)(4) of the FD&C Act at the time of approval or licensure. With this designation and upon approval of MER-101, Merlin would receive a Priority Review Voucher (PRV). A PRV is transferable and salable, have recently sold between $108M to $158M.

9/02/2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics Inc. [a PABC-resident company] announced the first patient has been dosed in the ACESOT-1051 Phase 1 study evaluating daily oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumor patients with unmet medical need. APR-1051 was discovered and preclinically evaluated by Aprea’s team of chemists and scientists.

6/24/2024

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers - Aprea Therapeutics

Aprea Therapeutics, Inc. announced that the FDA has cleared its Investigational New Drug application for APR-1051. “APR-1051 is a next-generation inhibitor of WEE1 kinase and, based on its unique characteristics, we believe it will be best in class,” said Dr. Oren Gilad, President and CEO of Aprea. “The FDA's clearance of our IND is a critical step in the APR-1051 development program. We look forward to evaluating therapeutic activity in patients, focusing on Cyclin E overexpressing cancers, including ovarian and breast cancers.”

3/11/2024

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies - GlobeNewswire

BriaCell Therapeutics Corp. (a resident company in B+labs at Cira Centre) announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.

3/07/2024

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Aprea Therapeutics, Inc., a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to initiate clinical trials of APR-1051. APR-1051 is an oral inhibitor of WEE1 kinase, which plays important role in cell cycle regulation and DNA damage repair.

2/06/2024

Newtown Resident Chari Cohen Wants to Help Eliminate Hepatitis B

“We are commanded to repair the world and make it a better place for everyone,” Cohen said. Since 1999, Cohen has done that. That was the year when the then-24-year-old got an internship at the Hepatitis B Foundation, the world’s only organization dedicated solely to fighting Hepatitis B.

1/17/2024

Merlin Biotech to Present at Biotech Showcase™ 2024

Merlin Biotech Inc. announced that it is presenting at Biotech Showcase™ 2024. This year, registered attendees can view Merlin’s presentation live, and with 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

1/07/2024

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and plans for advancement of its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024.

1/04/2024